Please login to the form below

Not currently logged in
Email:
Password:

Keryx Biopharmaceuticals

This page shows the latest Keryx Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU

Keryx Biopharmaceuticals' Fexeric approved in EU. New treatment option for chronic kidney disease. ... Keryx Biopharmaceuticals' Fexeric has been approved in Europe as a treatment for controlling phosphorus levels in adults with chronic kidney disease.

Latest news

  • Aeterna Zentaris under the cosh as myeloma candidate fails

    That result prompted the US developer of the drug, Keryx Biopharmaceuticals, to return rights to Aeterna Zentaris, which is also exploring the activity of perifosine in renal cell carcinoma, non-small

  • Extending the arsenal

    Introducing perifosine. Perifosine is a small-molecule compound that was originally discovered by Zentaris (now AEterna Zentaris) and has since been licensed to Keryx Biopharmaceuticals in the US, Canada and Mexico,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics